About SGN-CD19B

SGN-CD19B is an antibody-drug conjugate (ADC) targeted to CD19, a protein found broadly on B-cell hematologic malignancies. It uses our newest ADC technology, where the anti-CD19 antibody is attached with a stable linker to two molecules of a highly potent DNA crosslinking agent called a PBD (pyrrolobenzodiazepine) dimer.

This antibody-drug conjugate (ADC) is designed to be stable in the bloodstream, and to release its cytotoxic agent once inside the CD19-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.


Phase 1 trial evaluating safety and antitumor activity of SGN-CD19B in patients with B-cell non-Hodgkin lymphoma.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave